Lung Cancer | Specialty

Examining Key Data from DAREON-8

July 30th 2024

Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).

Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

July 30th 2024

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

Liquid Biopsy in Oncology: Have We Just Scratched the Surface?

July 30th 2024

Circulating tumor cells and circulating extracellular vesicles should be integrated into liquid biopsy assays to improve their utility in oncology.

Dr Patel on Areas of Advancement in the NSCLC Treatment Landscape

July 30th 2024

Sandip P. Patel, MD, discusses significant areas of advancements in the treatment paradigm for non–small cell lung cancer.

Dr Desai on Unmet Needs With Chemoimmunotherapy in NSCLC

July 30th 2024

akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer.

Dr Sen on the Goal to Identify Actionable Biomarkers of Interest in SCLC

July 30th 2024

Triparna Sen, PhD, discusses the importance of identifying actionable or targetable biomarkers for the management of small cell lung cancer.

Dr Peters on the Use of Biomarkers to Inform Treatment Decision-Making in NSCLC

July 30th 2024

Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer.

Dr Das on the ALINA Trial in Early-Stage ALK+ Lung Cancer

July 30th 2024

Millie Das, MD, discusses key trials that have advanced treatment for patients who present with non–small cell lung cancer.

Trastuzumab Deruxtecan in Patients With Metastatic Non-Small-Cell Lung Cancer (DESTINY-Lung01): Primary Results of the HER2 Overexpressing Cohorts From a Single-Arm, Phase 2 Trial

July 30th 2024

Misako Nagasaka, MD, PhD, discusses the use of trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer and recent NCCN guideline updates based on the DESTINY-Lung-01 HER2 overexpression cohort data.

Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

July 29th 2024

Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

July 29th 2024

China’s NMPA Accepts sBLA for Ivonescimab in First-Line PD-L1+ NSCLC

July 29th 2024

China’s NMPA has accepted an sBLA for ivonescimab in first-line, PD-L1–positive non–small cell lung cancer.

Experts Delve into Case-Based Discussions of Locally Advanced Lung Cancer Management

July 29th 2024

A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.

ctDNA Carves a Precise Path for Early-Stage NSCLC Management

July 29th 2024

David R. Gandara, MD, discusses research reflecting the capabilities of ctDNA assays to detect MRD and prognosticate adjuvant NSCLC treatment outcomes.

Dr Massarelli on Using Selpercatinib and Pralsetinib in Treating Advanced Non-Small Cell Lung Cancer

July 26th 2024

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC

July 26th 2024

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

CHMP Recommends Amivantamab Plus Chemo for Pretreated EGFR+ Advanced NSCLC

July 26th 2024

The EMA’s CHMP has recommended the approval of amivantamab plus chemotherapy for pretreated, EGFR-mutated advanced non–small cell lung cancer.

First-Line Sugemalimab Plus Chemo Wins European Approval for Metastatic NSCLC

July 26th 2024

First-line sugemalimab plus chemotherapy has been approved in Europe for metastatic non–small cell lung cancer.

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

July 26th 2024

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.

Dr Sands on the Evolving Role of ADCs in SCLC Management

July 25th 2024

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.